Recruiting
Phase 1
Phase 2

TNG462

Sponsor:

Tango Therapeutics, Inc.

Code:

NCT05732831

Conditions

Locally Advanced Solid Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

TNG462

Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-17. This information was provided to ClinicalTrials.gov by Tango Therapeutics, Inc. on 2025-04-06.